section ii company profile and financial highlights
i. company information
stock abbreviation | shanghai raas | stock code | 002252 |
stock exchange for listing | shenzhen stock exchange | ||
chinese name of the company | shanghai raas blood products co., ltd | ||
abbreviation for chinese name | shanghai raas | ||
company name in foreign language | shanghai raas blood products co., ltd. | ||
abbreviation for company name in foreign language | shanghai raas | ||
registered address | 2009 wangyuan road, fengxian district, shanghai 201401 | ||
office address | 2009 wangyuan road, fengxian district, shanghai 201401 | ||
website | www.raas-corp.com | ||
raas@raas-corp.com | |||
ii. contacts and contact details
secretary of board of directors | security affair representative | |
name | liu zheng | zhang yi |
address | wangyuan road 2009, fengxian district, shanghai | wangyuan road 2009, fengxian district, shanghai |
tel | 021-22130888-217 | 021-22130888-217 |
fax | 021-37515869 | 021-37515869 |
raas@raas-corp.com | raas@raas-corp.com |
iii. information disclosure and place
papers’ name of information disclosure chosen by the company | securities times, china securities journal, shanghai securities news and securities daily |
the website where semi-annual report is published appointed by china securities regulatory commission | www.cninfo.com.cn |
the place where the semi-annual report is set | shenzhen stock exchange, china securities regulatory commission shanghai branch and office of the board of directors of the company |
iv. change on registration
组织机构代码organization code | 统一社会信用代码913100006072419512 |
公司上市以来主营业务的变化情况 changes in major business since listed | 无变化。no change |
历次控股股东的变更情况 controlling shareholder change history | 公司前身上海莱士血制品有限公司由美国稀有抗体抗原供应公司和上海市血液中心血制品输血器材经营公司于1988年10月29日在上海合资成立。 2004年6月，原合资中方上海血液生物医药有限责任公司（上海市血液中心血制品输血器材经营公司2003年3月14日经上海市工商行政管理局核准更名为上海血液生物医药有限责任公司）将其持有的50.00%的股权转让给科瑞天诚。 2006年11月，公司原合资外方美国莱士将其持有的50.00%股权转让给莱士中国。 2007年1月17日，经中华人民共和国商务部商资批[2007]17号文批准，上海莱士血制品有限公司以2006年6月30日净资产12,000.00万元为基准，按1：1的比例折成12,000万股股本，依法整体变更为上海莱士血液制品股份有限公司。变更后上海莱士血制品有限公司的股东成为上海莱士的发起人股东，持股比例不变。 2007年3月1日，上海莱士取得企业法人营业执照，其中科瑞天诚和莱士中国各占50.00%股份。 自2007年3月1日至本报告期末，公司控股股东仍为科瑞天诚和莱士中国，期间，公司控股股东未曾发生变化。 the predecessor of the company is shanghai raas blood products co., ltd, which was established with joint-venture by rare antibody antigen supply, inc. (raas america) and shanghai blood center and blood transfusion equipment management company on october 29th, 1988. in june 2014, the original chinese party shanghai blood biological and pharmaceutical co., ltd (shanghai blood center and blood transfusion equipment management company was changed to chinese party shanghai blood biological and pharmaceutical co., ltd on march 14th 2003 through verification and approval of shanghai administrative bureau for industry and commerce) transferred its 50% equities to creat tiancheng. in november 2006, the original foreign party of the company raas america transferred its 50% equities to raas china. on january 17th 2007, shanghai raas blood products was changed with the net assets of rmb 120,000,000 yuan as of june 30th 2006 as the datum to be converted to 120,000,000 stocks upon 1:1 ratio through the approval of shang zi pi no. [2007]17 gained from ministry of commerce of p.r.c. after the change, the shareholders became the initiator shareholders of shanghai raas with the same proportion of stocks. on march 1st 2007, shanghai raas blood products co., ltd got its business license, of which creat tiancheng and raas china occupy 50% stocks respectively. from march 1st 2007 to the end of this reporting period, the controlling shareholders of the company are creat tiancheng and raas china, and there is no change on the controlling shareholders during the period. |
iiv. other related information
accounting firm employed by the company
name of accounting firm | dahua accounting firm (special general partnership) |
office address of accounting firm | 3/f changan building, 10 changan street, dongcheng district, beijing city |
name of certified public accountants for signature | zhang yan and tianyan ping |
sponsor agency employed by the company of performing continuous supervising responsibility during the reporting period
□ applicable √ n/a
financial consultant employed by the company of performing continuous supervising responsibility during the reporting period
√ applicable □ n/a
name of financial consultant | office address of financial consultant | name of the principal of the financial consultant | continuous supervising period |
citic securities co., ltd | north section, times square excellence (2nd phase), no. 8, third central road, futian district, shenzhen city, guangdong | huang jiang ning, you xiao fang | from january 22nd 2014 to the announcement date of the annual report of the first accounting year after the implementation of major assets reorganization project transaction. |
v. accounting and financial highlights
whether the company shall track and adjust or restate the former annual accounting data due to the change of accounting policies and correction of the mistakes made by the accountant
□ yes √ no
2015 | 2014 | increase or decrease of this year compared with the previous year (%) | 2013 | |
income (yuan) | 2,013,321,629.25 | 1,319,735,230.15 | 52.55% | 496,359,558.35 |
net profit attributable to the shareholders of the listed company (yuan) | 1,442,414,301.23 | 510,854,940.89 | 182.35% | 143,794,617.31 |
net profit attributable to the shareholders of the listed company with the excluded non-recurring profit and loss (yuan) | 682,328,492.46 | 481,830,905.14 | 41.61% | 142,443,993.74 |
net bal of cash flow from operation activities (yuan) | 763,150,968.59 | 465,961,164.58 | 63.78% | 90,108,107.96 |
basic earnings per share (yuan/share) | 0.52 | 0.22 | 136.36% | 0.07 |
diluted earnings per share (yuan/share) | 0.52 | 0.22 | 136.36% | 0.07 |
weighed average earnings rate of net asset (%) | 14.88% | 15.76% | -5.58% | 13.55% |
at the end of 2015 | at the end of 2014 | increase or decrease at end of this year compared with end of the previous year (%) | at the end of 2013 | |
total assets (yuan) | 11,556,011,686.37 | 9,379,458,963.86 | 23.21% | 1,575,146,803.85 |
net assets attributable to the shareholders of the listed company (yuan) | 10,658,472,403.13 | 8,609,713,428.08 | 23.80% | 1,087,234,758.71 |
total stocks of the company as of the one transaction day before the disclosure:
whether there is debt of the company
□ yes √ no
whether there is continuous loss condition in recent two years of the company
□ yes √ no
vi. difference between accounting standards inside and outside china
□ yes √ no
viii. quarterly financial highlights
in yuan
q1 | q2 | q3 | q4 | |
operating revenue | 356,171,273.00 | 460,419,291.90 | 675,371,970.36 | 521,359,093.99 |
net profit attributable to shareholders of listed company | 378,660,374.84 | 452,875,095.79 | 336,137,232.08 | 274,741,598.52 |
net profit attributable to shareholders of the company after non-recurring profit and loss | 104,617,964.61 | 167,829,604.40 | 278,671,476.65 | 131,209,446.79 |
net cash flow from operating activities | 69,962,976.40 | 212,672,344.90 | 235,983,091.23 | 244,532,556.06 |
are there any significant differences between the above financial indicators, total amount and those in disclosed quarterly reports and semi-annual report.
□ yes √ no
ix. non-recurring profit, loss and amount
□ applicable √ n/a
in yuan
item | amount in 2015 | amount in 2014 | amount in 2013 | note |
gains and losses from disposal of non-current assets (including the offset part counted in the provision for asset impairment) | -253,793.75 | -891,241.52 | -53,811.28 | |
government subsidies counted in current profit or loss (excluding the government subsidies closely related to the company’s business and fixed by china’s uniform standard) | 24,222,955.19 | 5,101,109.74 | 2,402,673.21 | |
profit and loss from the changes in fair value of held-for-trading financial assets and held-for-trading trading financial liabilities, as well as investment income from disposal of held-for-trading financial assets, held-for-trading trading financial liabilities and available-for-sale financial assets, except the effective hedging business related to the company’s normal operations | 874,929,178.81 | 31,453,349.65 | ||
non-operating income and expense other than the above items | -4,100,623.32 | -1,638,607.01 | -768,326.64 | |
other profit and loss in line with the definition of non-recurring profit and loss | 10,348.00 | |||
subtract: amount affected by income tax | 134,823,121.09 | 5,058,116.47 | 240,341.63 | |
amount affected by minority shareholders’ equity (after tax) | -111,212.93 | -47,193.36 | -10,429.91 | |
total | 760,085,808.77 | 29,024,035.75 | 1,350,623.57 | - |
the reason why non-recurring profit and loss items defined by the company in accordance with the "listed company information disclosure interpretation announcement no. 1 - non-recurring profit and loss" as well as those listed therein are defined as recurring profit and loss items shall be explained.
□ applicable √ n/a
links：
internet drug information service certificate :( shanghai) non-operating 2011-0201 九游会论坛 copyright © 2013-2014 shanghai raas all rights reserved powered by
"));
